Karen Briscoe

2.2k total citations
21 papers, 557 citations indexed

About

Karen Briscoe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Karen Briscoe has authored 21 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Pharmacology. Recurrent topics in Karen Briscoe's work include Cancer Immunotherapy and Biomarkers (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cannabis and Cannabinoid Research (3 papers). Karen Briscoe is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cannabis and Cannabinoid Research (3 papers). Karen Briscoe collaborates with scholars based in Australia, United Kingdom and United States. Karen Briscoe's co-authors include Pablo Fernández‐Peñas, Martin R. Stockler, Anna K. Nowak, Hui‐Ming Lin, Girish Mallesara, Brett Hughes, Lisa G. Horvath, Gavin Marx, Kate Mahon and Howard Gurney and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Karen Briscoe

20 papers receiving 550 citations

Peers

Karen Briscoe
Qiong Zhao China
Pei‐Yu Huang China
A. Jeanson France
Matilde Pensabene Italy
M Paesmans Belgium
V. Papadimitrakopoulou United States
Jun Koshio Japan
Manali Rupji United States
Christopher J. Darus United States
Silvia Bolzonello Italy
Qiong Zhao China
Karen Briscoe
Citations per year, relative to Karen Briscoe Karen Briscoe (= 1×) peers Qiong Zhao

Countries citing papers authored by Karen Briscoe

Since Specialization
Citations

This map shows the geographic impact of Karen Briscoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Briscoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Briscoe more than expected).

Fields of papers citing papers by Karen Briscoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Briscoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Briscoe. The network helps show where Karen Briscoe may publish in the future.

Co-authorship network of co-authors of Karen Briscoe

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Briscoe. A scholar is included among the top collaborators of Karen Briscoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Briscoe. Karen Briscoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahon, Kate, Hui‐Ming Lin, Martin R. Stockler, et al.. (2024). Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer. The Prostate. 84(8). 747–755. 5 indexed citations
2.
Lim, Annette M., Mathias Bressel, Jenny Lee, et al.. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. The Medical Journal of Australia. 220(2). 80–90. 8 indexed citations
3.
4.
Friedländer, Michael, Linda Mileshkin, Janine Lombard, et al.. (2023). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. British Journal of Cancer. 129(5). 797–810. 9 indexed citations
5.
Kirby, Adrienne, Martin R. Stockler, Annette Tognela, et al.. (2023). Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.. Journal of Clinical Oncology. 41(16_suppl). 12019–12019. 5 indexed citations
6.
Woodford, Rachel, Karen Briscoe, R. Don Tustin, & Ankit Jain. (2021). Immunotherapy-related gastritis: Two case reports and literature review. Clinical Medicine Insights Oncology. 15. 1353149530–1353149530. 9 indexed citations
7.
Nowak, Anna K., W. Joost Lesterhuis, Peey‐Sei Kok, et al.. (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology. 21(9). 1213–1223. 115 indexed citations
8.
9.
10.
11.
Nowak, Anna K., Peey‐Sei Kok, W. Joost Lesterhuis, et al.. (2018). OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result. Journal of Thoracic Oncology. 13(10). S338–S339. 25 indexed citations
12.
Lin, Hui‐Ming, Kate Mahon, Jacquelyn M. Weir, et al.. (2017). A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer. International Journal of Cancer. 141(10). 2112–2120. 63 indexed citations
13.
Lin, Hui‐Ming, Kate Mahon, Howard Gurney, et al.. (2017). Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer. 116(8). 1002–1011. 48 indexed citations
14.
Long, Georgina V., Jeffrey S. Weber, James Larkin, et al.. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. JAMA Oncology. 3(11). 1511–1511. 126 indexed citations
15.
16.
Tognela, Annette, David Espinoza, Andrew R. Davidson, et al.. (2016). Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non–small-cell lung cancer.. Journal of Clinical Oncology. 34(15_suppl). 9074–9074. 2 indexed citations
17.
Mahon, Kate, Hui‐Ming Lin, Howard Gurney, et al.. (2016). Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). 5039–5039. 1 indexed citations
18.
Ward, Robyn L., Aisling Kelly, Patricia Ryan, et al.. (2014). EviQ cancer treatments online (www.eviQ.org.au): A widely used Australian resource.. Journal of Clinical Oncology. 32(15_suppl). e17507–e17507. 3 indexed citations
19.
Blinman, Prunella, V. Duric, Anna K. Nowak, et al.. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. European Journal of Cancer. 46(10). 1800–1807. 33 indexed citations
20.
Rosen, D.J.D., et al.. (1979). Total care. Recent advances in the treatment of children with cancer.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 80(3). 113–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiong Zhao Breakdown of academic impact, for papers by Pei‐Yu Huang Breakdown of academic impact, for papers by A. Jeanson Breakdown of academic impact, for papers by Matilde Pensabene Breakdown of academic impact, for papers by M Paesmans Breakdown of academic impact, for papers by V. Papadimitrakopoulou Breakdown of academic impact, for papers by Jun Koshio Breakdown of academic impact, for papers by Manali Rupji Breakdown of academic impact, for papers by Christopher J. Darus Breakdown of academic impact, for papers by Silvia Bolzonello
Rankless by CCL
2026